The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
Launched by MASSACHUSETTS GENERAL HOSPITAL · May 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a rare condition called Recurrent Respiratory Papillomatosis (RRP), which is caused by certain types of the human papillomavirus (HPV). RRP can lead to growths in the respiratory system, particularly in the lungs, and currently, there are limited treatment options available. The goal of this study is to better understand how this disease affects the body and why the immune system struggles to fight it off. By examining the genetic and immune system changes in patients with RRP, researchers hope to discover new and effective treatments.
If you or a loved one has been diagnosed with HPV-associated RRP and has lung lesions, you may be eligible to participate in this study. There are no specific age or gender restrictions, and anyone with a history of the disease can join. Participants will undergo tests to help researchers learn more about the condition. This is an important step in developing better therapies for RRP, so if you are interested, consider talking to your healthcare provider for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • History of HPV-associated Recurrent Respiratory Papillomatosis
- • Has pulmonary lesions
- Exclusion Criteria:
- • None
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Patients applied
Trial Officials
Sara Pai
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported